0001401914 false Dare Bioscience, Inc. 0001401914 2023-06-21 2023-06-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549






Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 21, 2023



(Exact name of registrant as specified in its charter)


Delaware   001-36395   20-4139823

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)


Registrant’s telephone number, including area code: (858) 926-7655


Not Applicable

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock   DARE   Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 5.07 Submission of Matters to a Vote of Security Holders.


At the annual meeting of stockholders of Daré Bioscience, Inc. (“Daré,” “we,” “us,” or “our”) held on June 21, 2023, three proposals were voted upon by our stockholders. The proposals are described in detail in our definitive proxy statement for the meeting filed with the U.S. Securities and Exchange Commission on April 27, 2023. Below is a brief description of, and the final results of the votes for, each proposal.


Proposal 1: Each of the director nominees was elected as a Class III director to hold office until our 2026 annual meeting of stockholders, and until a successor is duly elected and qualified, by the votes set forth below.


Nominee  Votes For  Votes Withheld  Broker Non-Votes
Cheryl R. Blanchard, Ph.D.   22,509,430    3,095,043    24,268,923 
Sabrina Martucci Johnson   23,447,732    2,156,741    24,268,923 


Proposal 2: Our stockholders ratified the appointment of Mayer Hoffman McCann P.C.as our independent registered public accounting firm for the fiscal year ending December 31, 2023 by the votes set forth below.


Votes For  Votes Against  Abstentions  Broker Non-Votes
 48,270,018    1,341,227    262,151    


Proposal 3: Our stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement by the votes set forth below.


Votes For   Votes Against   Abstentions   Broker Non-Votes 
 22,399,824    3,026,516    178,133    24,268,923 






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: June 22, 2023 By: /s/ Sabrina Martucci Johnson
  Name: Sabrina Martucci Johnson
  Title: President and Chief Executive Officer